Policy. covered: bilateral. alcohol or. Approve. 3. Palliative enanthate injection in. women for. 6 months if. can also sponsive tumor.

Save this PDF as:
 WORD  PNG  TXT  JPG

Size: px
Start display at page:

Download "Policy. covered: bilateral. alcohol or. Approve. 3. Palliative enanthate injection in. women for. 6 months if. can also sponsive tumor."

Transcription

1 Injectablee Testosterone Products Prior Authorization Policy Number: Origination: 07/2014 Last Review: 07/2014 Next Review: 07/2015 Policy BCBSKC will provide coverage for injectable testosterone products when it is determined to be medically necessary because the following criteria are met. When Policy Topic is covered: Coverage of injectable testosterone (e.g., testosterone cypionate, testosteronee enanthate, Aveed, Testopel) is recommended in those who meet the following criteria: Food and Drug Administration (FDA)-Approved Indications 1. Hypogonadism (Primary or Secondary) in Males. Approve in patients with hypogonadism as confirmed by a low for age pre-treatment serum testosterone (total or free) level defined by the normal laboratory reference values. The injectable testosterone products are indicated for primary and secondary hypogonadism (congenital or acquired). Primary hypogonadism is testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, or orchidectomy, Klinefelter s syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. 1-3 Secondary (hypogonadotropic) hypogonadism is an idiopathic gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation. 2. Delayed Puberty or Inductionn of Puberty in Males 14 years of Age or Older. testosterone cypionate, testosterone enanthate, or Testopel for 6 months. Approve Evidencee supports the use of injectable testosterone agents for delayed puberty. 11 efficacy of Aveed in males < 18 years of age have not been established. 7 The safety and 3. Palliative Treatment of Inoperable Metastatic Breast Cancer in Females. Approve testosterone enanthate injection in women for 6 months if it is prescribed by or in consultationn with an oncologist. Testosterone enanthate may be used secondarily in women with advanced inoperable metastatic breast cancer that are 1 to 5 years postmenopausal. 2 The goal of therapy is ablation of ovaries. It can also be used in premenopausal women with breast cancer that have benefited from oophorectomy and are considered to have hormone-res sponsive tumor. Other Uses with Supportive Evidence 4. Female-to-Male (FTM) Gender Reassignment (i.e., Endocrinologic Masculinization). Approve if prescribed by or in consultation with an endocrinologist or a physician who specializes in the treatment of transgender patients. Clinical studies have demonstrated the efficacy of several different androgen preparations (i.e., oral, parenteral, or transdermal testosterone) to induce masculinizationn in FTM transsexual persons. 12

2 Regimens to change secondary sex characteristics follow the general principle of hormone replacement treatment of male hypogonadism. A clinical practice guideline published by the Endocrine Society, recommends that, prior to initiation of hormonal therapy, the treating endocrinologist should confirm the diagnostic criteria for gender identification disorder (GID) or transsexualism and the eligibility and readiness criteria for the endocrine phase of gender transition. The endocrinologist should also review the onset and time course of physical changes induced by cross-sex hormone treatment. When Policy Topic is not covered: Injectable testosterone (e.g., testosterone cypionate, testosterone enanthate, Aveed, Testopel) has not been shown to be effective, or there are limited or preliminary data or potential safety concerns that are not supportive of general approval for the following conditions. Rationale for non-coverage for these specific conditions is provided below. (Note: This is not an exhaustive list of Conditions Not Recommended for Approval.) 1. Use in Females for Indications Other than Female-to-Male (FTM) Gender Reassignment and Palliative Treatment of Metastatic Breast Cancer (see above). All of the injectable testosterone products are contraindicated for use in pregnant women. 1-3 In the 2006 guidelines on androgen therapy in women from the Endocrine Society, despite some short-term efficacy evidence, it recommends against the generalized use of testosterone by women because the indications are inadequate and the evidence of safety in long-term (> 24 weeks) studies is lacking. 13 The American College of Obstetricians and Gynecologists (ACOG) clinical management guidelines for management of female sexual dysfunction (reaffirmed in 2013) mentions testosterone as an option for the short-term treatment (e.g., 6 months) of hypoactive sexual desire disorder. 14 However, the FDA-approved testosterone formulations provide doses larger than the dosages studied in and typically required by women. More data are needed regarding long-term safety of testosterone use in women and patient selection before it can be recommended in this patient population. Testosterone supplementation has also been evaluated in a small number of women for the effect on follicle stimulation with no significant effect noted To Enhance Athletic Performance. Injectable testosterone products are not recommended for approval because this indication is excluded from coverage in a typical pharmacy benefit. 3. Use in Males with Carcinoma of the Breast. All of these testosterone replacement products are contraindicated for use in men with carcinoma of the breast Use in Males with Known or Suspected Carcinoma of the Prostate (excluding males with treated and cured prostate cancer). All of these testosterone replacement products are contraindicated for use in men with known or suspected carcinoma of the prostate. 1-3 Considerations Injectable testosterone products require prior authorization through the pharmacy services department. This Blue Cross and Blue Shield of Kansas City policy Statement was developed using available resources such as, but not limited to: Hayes Medical Technology Directory, Food and Drug Administration (FDA) approvals, Facts and Comparisons, National specialty guidelines, Local medical policies of other health plans, Medicare (CMS), Local providers. Description of Procedure or Service Endogenous androgens are responsible for the normal growth and development of the male sex organs and for maintenance of secondary sex characteristics. 1-3 Some of these effects include alterations in body musculature, maturation of prostate, seminal vesicles, penis and scrotum. Androgens are also responsible for the growth spurt of adolescence and for the eventual termination of linear growth. Exogenous androgens in children can accelerate linear growth rates but may also cause a disproportionate advancement in bone maturation.

3 Testosterone replacement regimens supply exogenous testosterone and restore serum testosterone levels in the normal range (300 to 1,000 ng/dl). 4 The International Society of Andrology (ISA), International Society for the Study of the Aging Male (ISSAM), European Association of Urology (EAU), European Academy of Andrology (EAA), and the American Society of Andrology (ASA) propose 230 ng/dl as the lower limit of serum testosterone at which patients will benefit from testosterone replacement therapy. 5 The Endocrine Society recommends 300 ng/dl, and the American Association of Clinical Endocrinolgoists (AACE) suggests 200 ng/dl as the lower limit for testosterone replacement. Testosterone level increases in males until 17 years of age and stabilizes to a serum level in the range of 300 to 1,000 ng/dl, until about 40 years of age. After this, the levels begin to decline at 1.2% to 2% per year. About 20% of men > 60 years of age and 50% of men > 80 years of age are estimated to have serum testosterone levels that are subnormal compared with younger men. Given this inherent variability in testosterone levels in men based on age, it is also prudent to consider other variables that could affect a lab drawn testosterone level (e.g., time of day when the level is drawn, laboratory specific normal values for testosterone, total vs. free testosterone levels) before initiating replacement therapy. Male hypogonadism is characterized by low serum levels of testosterone and is classified according to the level of the hypothalamus-pituitary-testis axis involvement. 6 It is classified as primary hypogonadism when the main problem involves the testes (elevated lutenizing hormone [LH] and follicle stimulating hormone [FSH]). It is secondary hypogonadism (hypogonadotropic hypogonadism) if the hypothalamus/pituitary axis are involved; low testosterone levels in this case are associated with low or inadequately normal levels of LH and FSH. The diagnosis of male hypogonadism is based on both a clinical suspicion and low testosterone levels. By restoring normal levels of testosterone, the replacement regimens correct symptoms of hypogonadism, which can include malaise, loss of muscle strength, depressed mood, and decreased libido. 4 Testosterone regimens can be administered orally, parenterally, or transdermally. Injectable testosterone replacement products include testosterone cypionate, testosterone enanthate, Aveed, and Testopel, which is implanted subcutaneously. 4,7 These agents are all indicated for congenital or acquired primary hypogonadism and hypogonadotropic hypogonadism (secondary hypogonadism). 1-3 Testopel and testosterone enanthate are also indicated for delayed puberty. 2-3 Testosterone enanthate may also be used secondarily in women with advanced inoperable metastatic mammary cancer that are 1 to 5 years postmenopausal. 2 The primary goal of this therapy is to ablate the ovaries. It can also be used in premenopausal women with breast cancer that have benefited from oophorectomy and are considered to have hormone-responsive tumor. The prescribing information notes that the judgement regarding the use of androgen therapy in females should be made by an oncologist with expertise in the area. Compared to the other two intramuscular injections, Aveed has a longer duration between dosing after it reaches steady state levels. 7 After the first injection, a second injection is administered after 4 weeks. After this second dosing, the subsequent administration are once every 10 weeks. Dose titration is not necessary. The safety and efficacy of Aveed in males < 18 years of age have not been established. Rationale Guidelines American Urological Association (AUA) A white paper published by the American Urological Association (AUA) [2013] notes the challenges in establishing a universally accepted threshold for testosterone concentration that distinguishes eugonadal from hypogonadal men. 8 The AUA notes that there are several different assays for measurement of testosterone levels, and that the performance characteristics, linearity, reproducibility, low level limits of detection, and the pre-analytical requirements differ among the assays. The Endocrine Society recommends that total low testosterone be defined using local, normal assay ranges in the presence of characteristic signs and symptoms diagnostic of hypogonadism. The AUA states that the rigid use of testosterone cut-off value (e.g., 300 ng/dl) may lead to unnecessary treatment of asymptomatic men as well as under-treatment of men with persistent signs and symptoms.

4 Endocrine Society The Endocrine Society guidelines (2010) on testosterone therapy in adult men with androgen deficiency recommend testosterone therapy for symptomatic men with the classical androgen deficiency syndromes who have low testosterone levels. 9 The purpose is to induce and maintain secondary sex characteristics and to improve their sexual function, sense of well-being, muscle mass and strength, and bone mineral density. The guidelines also suggest aiming for serum testosterone levels in the midnormal range with testosterone replacement therapy. They list several options for replacement and note that the choice can be based on the patient s preference, consideration of pharmacokinetics, treatment burden, and cost. The options listed are injectable testosterone enanthate or cypionate, nongenital testosterone patches, testosterone gel, bioadhesive buccal testosterone tablet, or oral testosterone undecanoate (not available in the US), injectable testosterone undecanoate (not available in the US), and testosterone pellets. The World Professional Association for Transgender Health (WPATH) The WPATH Standards of Care document (2011) states that exogenous administration of hormone therapy to induce feminizing or masculinizing changes is a medically necessary intervention for many transsexual, transgender, and gender nonconforming individuals with gender dysphoria. 10 Hormone therapy must be individualized based on the patient s goals, risk/benefit ratio of the medications, presence of other co-morbid conditions, and social/economic issues. Hormone therapy alone can provide significant comfort to patients who do not wish to make a social gender role transition, undergo surgery, or in patients unable to have surgery. References: 1. Depo -Testosterone [prescribing information]. New York, NY: Pharmacia & Upjohn Co; September Delatestryl [prescribing information]. Lexington, MA: Indevus Pharmaceuticals, Inc.; July Testopel [prescribing information]. Morrisville, NC: Slate Pharma; January Lee M. Erectile Dysfunction. Urologic Disorders. In: Dipiro JT, Talbert RL, Yee GC, et al, eds. Pharmacotherapy: A pathophysiologic approach. 8 th ed. New York: McGraw Hill Medical; 2008: Abadilla KA, Dobs AS. Topical testosterone supplementation for the treatment of male hypogonadism. Drugs. 2012;72: Giagulli VA, Triggiani V, Corona G, et al. Evidence-based medicine update on testosterone replacement therapy (TRT) in male hypogonadism: Focus on new formulations. Curr Pharm Des. 2011;17: Aveed [prescribing information0. Malvern, PA: Endo Pharmaceuticals Solutions Inc.; March Paduch DA, Brannigan RE, Fuchs EF, et al. The laboratory diagnosis of testosterone deficiency. White paper. American Urological Association, Inc. Available at: WhitePaper.pdf. Accessed on October 2, Bhasin S, Cunningham GR, Hayes FJ, et al. Testosterone therapy in adult men with androgen deficiency syndromes: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2010;95(6): Coleman E, Bockting W, Botzer M, et al. Standards of care for the health of transsexual, transgender, and gender nonconforming people. The World Professional Association for Transgender Health. 7 th Version. International Journal of Transgenderism. 2011;13: Palmert MR, Dunkel L. Clinical Practice. Delayed Puberty. N Engl J Med. 2012;366: Hembree WC, Cohen-Kettenis P, Delemarre-van de Waal HA, et al. Endocrine treatment of the transsexual persons: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2009; 94: Wierman ME, Basson R, Davis SR, et al. Androgen therapy in women: an Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2006;91(10):

5 14. American College of Obstetricians and Gynecologists Committee on Practice Bulletins-Gynecology. ACOG Practice Bulletin No. 119: Female sexual dysfunction. Obstet Gynecol. 2011;117(4): (reaffirmed 2013). 15. Sipe CS, Thomas MR, Stegmann BJ, van Voorhis BJ. Effects of exogenous testosterone supplementation in gonadotrophin stimulated cycles. Hum Reprod. 2010;25(3): Billing Coding/Physician Documentation Information NA Additional Policy Key Words Policy Number: Related Topics N/A Policy Implementation/Update Information 07/2014 New Policy titled Injectable Testosterone Products Prior Authorization This Medical Policy is designed for informational purposes only and is not an authorization, an explanation of benefits, or a contract. Each benefit plan defines which services are covered, which are excluded, and which are subject to dollar caps or other limits. Members and their providers will need to consult the member's benefit plan to determine if there is any exclusion or other benefit limitations applicable to this service or supply. Medical technology is constantly changing and Blue Cross and Blue Shield of Kansas City reserves the right to review and revise medical policy. This information is proprietary and confidential and cannot be shared without the written permission of Blue Cross and Blue Shield of Kansas City.

Testosterone Topical/Buccal/Nasal

Testosterone Topical/Buccal/Nasal BENEFIT APPLICATION Testosterone Topical/Buccal/Nasal DRUG POLICY Benefit determinations are based on the applicable contract language in effect at the time the services were rendered. Exclusions, limitations

More information

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol

Testosterone Hormone Replacement Drug Class Prior Authorization Protocol Line of business: Medi-Cal Effective Date: August 16, 2017 Revision Date: August 16, 2017 Testosterone Hormone Replacement Drug Class Prior Authorization Protocol This policy has been developed through

More information

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES

HARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES Generic Brand HICL GCN Exception/Other METHYL ANDROID METHITEST METHYL TESTRED 01404 ROUTE MISCELL. CYPIONATE ENANTHATE GUIDELINES FOR USE ANDRODERM ANDROGEL AXIRON FORTESTA NATESTO STRIANT TESTIM VOGELXO

More information

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information. Clinical Policy: Reference Number: CP.CPA.291 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory

More information

UnitedHealthcare Pharmacy Clinical Pharmacy Programs

UnitedHealthcare Pharmacy Clinical Pharmacy Programs UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 2018-9 Program Prior Authorization/Medical Necessity Topical Androgens Medication Axiron*, Androderm, Androgel*, Fortesta*, Natesto*,

More information

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens and Anabolic Steroids Prior Authorization with Quantity Limit - Through Preferred Topical Androgen Agent Androgens/Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred

More information

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred Topical Androgen Criteria Program Summary

Androgens and Anabolic Steroids Prior Authorization with Quantity Limit Through Preferred Topical Androgen Criteria Program Summary OBJECTIVE The intent of the Androgens and Anabolic Steroids Prior Authorization with Quantity Limit (PA) program is to appropriately select patients for therapy according to product labeling and/or clinical

More information

Medical Policy Testosterone Therapy

Medical Policy Testosterone Therapy Medical Policy Testosterone Therapy Subject: Testosterone Therapy Effective Date: April 2015 Overview: Testosterone cypionate, testosterone enanthate, testosterone undecanoate, and testosterone pellet

More information

Current Data and Considerations Novel Testosterone Formulations

Current Data and Considerations Novel Testosterone Formulations Current Data and Considerations Novel Testosterone Formulations 1 Current and Novel Therapeutic Options Module 4 2 Objectives Identify desirable characteristics of ideal testosterone formulations Review

More information

TREATMENT OPTIONS FOR MALE HYPOGONADISM

TREATMENT OPTIONS FOR MALE HYPOGONADISM TREATMENT OPTIONS FOR MALE HYPOGONADISM Bruce Biundo, RPh, FACA PCCA Pharmacy Consulting Department Updated July 2012 Hypogonadism in men is primarily a state involving lower than expected levels of testosterone,

More information

Insight into male menopause'

Insight into male menopause' Insight into male menopause' Dr Mark Vanderpump MD FRCP Consultant Endocrinologist Clinics: Tuesday PM Mark Vanderpump Consultant Physician and Endocrinologist Introduction Serum total and free testosterone

More information

PRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate)

PRODUCT INFORMATION TESTOVIRON DEPOT. (testosterone enanthate) PRODUCT INFORMATION TESTOVIRON DEPOT (testosterone enanthate) NAME OF THE MEDICINE Testosterone enanthate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of

More information

Testosterone Replacement Therapy

Testosterone Replacement Therapy 30 Bond Street, Toronto ON, M5B 1W8 www.odprn.ca info@odprn.ca Testosterone Replacement Therapy Environmental Scan and Local/Historical Context December 1, 2014 2 Executive Summary Part A: Pharmacy Benefit

More information

1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride

1001 West Broadway, Vancouver, BC V6H 4B1. Topical Finasteride 1001 West Broadway, Vancouver, BC V6H 4B1 Topical Finasteride 1 Topical finasteride is a solution containing the drug finasteride typically sold under the brand names Propecia and Proscar. The Finasteride

More information

Male Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2

Male Hormone Replacement Therapy. Punita Dhindsa D.O PGY 2 Male Hormone Replacement Therapy Punita Dhindsa D.O PGY 2 Physiology of Testosterone & Causes of Hypogonadism in Males The use of testosterone therapy is very common in the US, with an estimated 2.3 million

More information

FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM

FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM 750 West Broadway Street Suite 905 Vancouver, BC M5Z 1K1 FAX: (604) 648-9003 vancouveroffice@donovanmedical.com FINASTERIDE (PROPECIA, PROSCAR) SIDE EFFECT & CONSENT FORM What is finasteride? Finasteride

More information

NEW ZEALAND DATA SHEET

NEW ZEALAND DATA SHEET NEW ZEALAND DATA SHEET 1. PRODUCT NAME DEPO-TESTOSTERONE 100mg/mL Solution for Injection 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each 1 ml solution for injection contains 100 mg/ml testosterone cypionate.

More information

Testosterone for Sale

Testosterone for Sale Testosterone for Sale Testosterone (C 19 H 28 O 2 ) is the male hormone. The brain, the pituitary gland, and the testes must work in perfect harmony to produce adequate amounts of it. If you want to know

More information

PRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate)

PRODUCT INFORMATION PRIMOTESTON DEPOT. (testosterone enantate) PRODUCT INFORMATION PRIMOTESTON DEPOT (testosterone enantate) NAME OF THE MEDICINE Testosterone enantate is designated chemically as 17 beta-heptanoyloxy-4-androstene-3- one. The empirical formula of testosterone

More information

pump. a metered-dose pump that delivers 30 mg of testosterone per twist. Each metered-dose pump is supplied with an applicator.

pump. a metered-dose pump that delivers 30 mg of testosterone per twist. Each metered-dose pump is supplied with an applicator. 1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AXIRON safely and effectively. See full prescribing information for AXIRON. AXIRON (testosterone)

More information

Package Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters)

Package Leaflet: Information for the patient. Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Package Leaflet: Information for the patient Sustanon 250, 250 mg/ml, solution for injection (testosterone esters) Read all of this leaflet carefully before you start using this medicine because it contains

More information

Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism

Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism Brigham Young University BYU ScholarsArchive All Student Publications 2016-07-27 Comparison of Testosterone Replacement Therapy Medications in the Treatment of Hypogonadism Christopher M. Williams Brigham

More information

4.2 Posology, method and duration of administration

4.2 Posology, method and duration of administration The format of this leaflet was determined by the Ministry of Health and its content was checked and approved by it in May 2011. 1. NAME OF MEDICINAL PRODUCT Testoviron Depot Oily solution for injection

More information

PRODUCT INFORMATION PROVIRON

PRODUCT INFORMATION PROVIRON PRODUCT INFORMATION PROVIRON NAME OF TE MEDICINE Mesterolone is a white to yellowish crystalline powder and is practically insoluble in water. The chemical name for mesterolone is 17 beta-ydroxy-1 alpha-methyl-5

More information

TESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc.

TESTOFEN HUMAN CLINICAL TRIAL GENCOR PACIFIC, INC. Copyright 2006 by Gencor Pacific, Inc. GENCOR PACIFIC, INC. 920 E. Orangethorpe Avenue, Suite B, Anaheim, CA 92801 Ph: 714.870.8723 714.870.8724 efax: 732.875.0306 drjit@gencorpacific.com gita@gencorpacific.com www.gencorpacific.com TESTOFEN

More information

ANDROGENS PLAY AN essential role in the sexual

ANDROGENS PLAY AN essential role in the sexual 0021-972X/04/$15.00/0 The Journal of Clinical Endocrinology & Metabolism 89(11):5429 5434 Printed in U.S.A. Copyright 2004 by The Endocrine Society doi: 10.1210/jc.2004-0897 Intramuscular Testosterone

More information

HGH for Sale Natural Anti-Aging Human Growth Hormone

HGH for Sale Natural Anti-Aging Human Growth Hormone HGH for Sale Natural Anti-Aging Human Growth Hormone Human growth hormone is one of the hottest supplement trends on the market, and now you can purchase top-quality HGH to be delivered right to your home!

More information

PRESCRIBING INFORMATION

PRESCRIBING INFORMATION PRESCRIBING INFORMATION C DELATESTRYL* testosterone enanthate Solution for Injection, 200 mg/ml Androgens Valeant Canada LP 2150 Blvd. St-Elzear West Laval, Quebec H7L 4A8 Date of Revision: August 19,

More information

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 20 June 2012 The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION 20 June 2012 CINRYZE 500 units, 2100 IU, powder and solvent for solution for injection B/2 bottles (CIP code: 218

More information

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended

Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Public Assessment Report for paediatric studies submitted in accordance with Article 45 of Regulation (EC) No1901/2006, as amended Andriol Testocaps, Sustanon and Testosterone Implants [] NL/W/0026/pdWS/001

More information

Maturitas 67 (2010) Contents lists available at ScienceDirect. Maturitas. journal homepage:

Maturitas 67 (2010) Contents lists available at ScienceDirect. Maturitas. journal homepage: Maturitas 67 (2010) 39 45 Contents lists available at ScienceDirect Maturitas journal homepage: www.elsevier.com/locate/maturitas Review Androgen deficiency in women; role of accurate testosterone measurements

More information

HGH for Sale Human Growth Hormone

HGH for Sale Human Growth Hormone HGH for Sale Human Growth Hormone Many people consider HGH for sale, or Human Growth Hormone (C 990 H 1529 N 263 O 299 S 7 ) the fountain of youth. In fact, many experts suggest that this is the most sought-after

More information

Pathways and manipulation of testosterone biosynthesis and metabolism

Pathways and manipulation of testosterone biosynthesis and metabolism Pathways and manipulation of testosterone biosynthesis and metabolism Dihydrotestosterone 8% Pregnenolone 3-βSD Progesterone 17- Pregnenolone 17a--lase 17-Progesterone 3-βSD 17a--lase Androstenedione DEA

More information

NATESTO Testosterone nasal gel 4.5% w/w

NATESTO Testosterone nasal gel 4.5% w/w PRODUCT MONOGRAPH INCLUDING PATIENT MEDICATION INFORMATION NATESTO Testosterone nasal gel 4.5% w/w Androgens Acerus Pharmaceuticals SRL Durants, Business Centre, Suite B Durants, Christ Church Barbados,

More information

Health Products Regulatory Authority

Health Products Regulatory Authority 1 NAME OF THE VETERINARY MEDICINAL PRODUCT Myodine 25 mg/ml solution for injection for dogs and cats 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each ml contains: Active substance: Nandrodine laurate 25

More information

Testosterone Use and Effects

Testosterone Use and Effects Parkland College Natural Sciences Poster Sessions Student Works 2013 Testosterone Use and Effects Brandon Mills Parkland College Recommended Citation Mills, Brandon, "Testosterone Use and Effects" (2013).

More information

DUPROST Capsules (Dutasteride)

DUPROST Capsules (Dutasteride) Published on: 10 Jul 2014 DUPROST Capsules (Dutasteride) Composition Each soft gelatin capsule contains: Dutasteride... 0.5 mg Dosage Form Capsule Pharmacology Pharmacodynamics Mechanism of Action Dutasteride

More information

Anavar For Sale Oxandrolone

Anavar For Sale Oxandrolone Anavar For Sale Oxandrolone Anavar (oxandrolone C 19 H 30 O 3 ) is an anabolic steroid that provides outstanding results. The Anavar steroid is a synthesized version of testosterone that boosts lean muscle

More information

Transsexuals and competitive sports

Transsexuals and competitive sports European Journal of Endocrinology (2004) 151 425 429 ISSN 0804-4643 REVIEW Transsexuals and competitive sports Louis J G Gooren and Mathijs C M Bunck Department of Endocrinology, Section of Andrology,

More information

Enhanced Linear Growth Responses in Hypopituitary Dwarfs Treated with Growth Hormone Plus Androgen versus Growth Hormone Alone

Enhanced Linear Growth Responses in Hypopituitary Dwarfs Treated with Growth Hormone Plus Androgen versus Growth Hormone Alone Pediat. Res. 8: 103-108 (1974) Androgen growth hormone fluoxymesterone hypopituitary dwarfs Enhanced Linear Growth Responses in Hypopituitary Dwarfs Treated with Growth Hormone Plus Androgen versus Growth

More information

Case ILN/1:14-cv Document 1 Filed 04/30/14 Page 1 of 10 BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION ) ) ) ) ) )

Case ILN/1:14-cv Document 1 Filed 04/30/14 Page 1 of 10 BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION ) ) ) ) ) ) Case ILN/1:14-cv-02934 Document 1 Filed 04/30/14 Page 1 of 10 BEFORE THE JUDICIAL PANEL ON MULTIDISTRICT LITIGATION IN RE: ANDROGEL PRODUCTS LIABILITY LITIGATION MDL DOCKET NO. 2545 OPPOSITION OF DEFENDANTS

More information

WADA Technical Document TD2014EAAS. Endogenous Anabolic Androgenic Steroids Measurement and Reporting

WADA Technical Document TD2014EAAS. Endogenous Anabolic Androgenic Steroids Measurement and Reporting Endogenous Anabolic Androgenic Steroids Measurement and Reporting 1.0 Introduction The purpose of this Technical is to harmonize the approaches to the measurement and reporting of endogenous anabolic androgenic

More information

FULL PRESCRIBING INFORMATION

FULL PRESCRIBING INFORMATION HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use AVODART safely and effectively. See full prescribing information for AVODART. AVODART (dutasteride)

More information

Androgen deficiency in the aging male

Androgen deficiency in the aging male Androgen deficiency in the aging male Practice Committee of the American Society for Reproductive Medicine in collaboration with the Society for Male Reproduction and Urology The American Society for Reproductive

More information

PROPECIA (Finasteride) Tablets, 1 mg

PROPECIA (Finasteride) Tablets, 1 mg 9328502 PROPECIA (Finasteride) Tablets, 1 mg DESCRIPTION PROPECIA * (finasteride), a synthetic 4-azasteroid compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that

More information

The Football Association Policy on Trans People in Football

The Football Association Policy on Trans People in Football POLICY DOCUMENT 1. Introduction Football belongs to, and should be enjoyed by, anyone who wants to participate in it. The Football Association (The FA) regulates the participation of competitors in football

More information

Antiduretic Hormone, Growth. Hormone & Anabolic Steroids

Antiduretic Hormone, Growth. Hormone & Anabolic Steroids Goudarz Sadeghi, DVM, PhD, DSc Associate Professor of Pharmacology University of Tehran Faculty of Veterinary Medicine Veterinary Pharmacology Endocrine System Antiduretic Hormone, Growth Hormone & Anabolic

More information

Andropause How Relevant?

Andropause How Relevant? Andropause How Relevant? 323 55 Andropause How Relevant? VN MISHRA, NALINI MISHRA INTRODUCTION In day-to-day practice it is not unusual to encounter male patients in their 50s or older who come to physician

More information

The Football Association Policy on Trans People in Football

The Football Association Policy on Trans People in Football FREQUENTLY ASKED QUESTIONS Frequently Asked Questions (FAQ) 1. What is The FA policy on transgender or transsexual people playing football? The FA s policy on transgender or transsexual people playing

More information

ARE FINASTERIDE SIDE EFFECTS PERMANENT

ARE FINASTERIDE SIDE EFFECTS PERMANENT ARE FINASTERIDE SIDE EFFECTS PERMANENT Are Finasteride Side Effects Permanent Finasteride side effects in pregnant women Finasteride and dutasteride at the same time Does finasteride cause dizziness 1

More information

PROPECIA finasteride 1 mg tablet

PROPECIA finasteride 1 mg tablet Name of Medicine PROPECIA finasteride 1 mg tablet Presentation A tan octagonal convex tablet embossed with a P logo on one side and PROPECIA on the other. Diameter: 7.14 mm. Therapeutic Class PROPECIA

More information

Diabetes and Recreational Diving

Diabetes and Recreational Diving Guidelines for Diabetes and Recreational Diving Proceedings Summary DAN/UHMS Diabetes and Recreational Diving Workshop 1 Proceedings Summary DAN/UHMS Diabetes and Recreational Diving Workshop DAN.org Introduction

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION AVODART SOFT CAPSULES 0.5 MG 1. NAME OF THE MEDICINAL PRODUCT Avodart 0.5 mg capsules, soft. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. For excipients, see 6.1.

More information

PROPECIA (finasteride) Tablets, 1 mg

PROPECIA (finasteride) Tablets, 1 mg 9328505 PROPECIA (finasteride) Tablets, 1 mg DESCRIPTION PROPECIA * (finasteride), a synthetic 4-azasteroid compound, is a specific inhibitor of steroid Type II 5α-reductase, an intracellular enzyme that

More information

WADA Technical Document TD2018MRPL

WADA Technical Document TD2018MRPL MINIMUM REQUIRED PERFORMANCE LEVELS FOR DETECTION AND IDENTIFICATION OF NON-THRESHOLD SUBSTANCES In order to ensure that all WADA-accredited Laboratories can report the presence of Prohibited Substances,

More information

Development of a Clinical Research Method for the Measurement of Testosterone. Dihydrotestosterone

Development of a Clinical Research Method for the Measurement of Testosterone. Dihydrotestosterone Development of a Clinical Research Method for the Measurement of Testosterone and Dihydrotestosterone Martijn van Faassen, Maarten van den Noort and Ido Kima University Medical Center, Groningen, Netherlands

More information

REPRODUCTIVE ENDOCRINOLOGY

REPRODUCTIVE ENDOCRINOLOGY FERTILITY AND STERILITY VOL. 79, NO. 1, JANUARY 2003 Copyright 2003 American Society for Reproductive Medicine Published by Elsevier Science Inc. Printed on acid-free paper in U.S.A. REPRODUCTIVE ENDOCRINOLOGY

More information

SIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE

SIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE SIMPLE, EFFICIENT AND SIMULTANEOUS DETERMINATION OF ANABOLIC STEROIDS IN HUMAN URINE Pages with reference to book, From 216 To 218 S.J. Khurshid, M. Riaz, S. Ahmed ( Nuclear Chemistry Division, Pakistan

More information

2. QUALITATIVE AND QUANTITATIVE COMPOSITION

2. QUALITATIVE AND QUANTITATIVE COMPOSITION AVODART SOFT CAPSULES 0.5 MG 1. NAME OF THE MEDICINAL PRODUCT AVODART 0.5 mg capsules, soft. 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each capsule contains 0.5 mg dutasteride. For excipients, see 6.1.

More information

Introduction to the Doping Problem

Introduction to the Doping Problem Introduction to the Doping Problem Jordi Segura Director, WADA Accredited Antidoping Laboratory, IMIM-Hospital del Mar, Barcelona, Spain Doping and Society: towards the perfect human machine? ESOF, Barcelona

More information

WEIGHT LOSS DURING THE

WEIGHT LOSS DURING THE ORIGINAL CONTRIBUTION Testosterone Replacement and Resistance in HIV-Infected Men With Weight Loss and Low Testosterone Levels Shalender Bhasin, MD Thomas W. Storer, PhD Marjan Javanbakht, MPH Nancy Berman,

More information

Product Monograph. Sandoz Dutasteride

Product Monograph. Sandoz Dutasteride Product Monograph Pr Sandoz Dutasteride Dutasteride Capsules of 0.5 mg Type I and II 5 Alpha-reductase Inhibitor Sandoz Canada Inc. 145 Jules-Léger Boucherville, QC, Canada J4B 7K8 Date of Preparation:

More information

The New England Journal of Medicine

The New England Journal of Medicine The New England Journal of Medicine Copyright, 1996, by the Massachusetts Medical Society VOLUME 335 J ULY 4, 1996 NUMBER 1 THE EFFECTS OF SUPRAPHYSIOLOGIC DOSES OF TESTOSTERONE ON MUSCLE SIZE AND STRENGTH

More information

AVODART (dutasteride) Soft Gelatin Capsules

AVODART (dutasteride) Soft Gelatin Capsules AVODART (dutasteride) Soft Gelatin Capsules PRESCRIBING INFORMATION DESCRIPTION AVODART (dutasteride) is a synthetic 4-azasteroid compound that is a selective inhibitor of both the type 1 and type 2 isoforms

More information

FINASTERIDE PER ALOPECIA ANDROGENETICA FEMMINILE

FINASTERIDE PER ALOPECIA ANDROGENETICA FEMMINILE FINASTERIDE PER ALOPECIA ANDROGENETICA FEMMINILE ### 1 finasteride and depression Should finasteride be taken in am or pm, finasteride 5mg tab bald blog post ideas efectos. 2 Finasteride testosterone replacement

More information

Pharmacology of testosterone preparations

Pharmacology of testosterone preparations 14 Pharmacology of testosterone preparations H.M. Behre, C. Wang, D.J. Handelsman and E. Nieschlag Contents 14.1 Historical development of testosterone therapy 14.2 General considerations 14.3 Pharmacology

More information

Presidential address of the American Orthopaedic Society for Sports Medicine Drug abuse in sports*

Presidential address of the American Orthopaedic Society for Sports Medicine Drug abuse in sports* Presidential address of the American Orthopaedic Society for Sports Medicine Drug abuse in sports* JAY S. COX, MD President, AOSSM The reasons that athletes use drugs are to improve performance, to play

More information

Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy

Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy British Journal of Dermatology (1986) 115, 269-274. Control of hidradenitis suppurativa in women using combined antiandrogen (cyproterone acetate) and oestrogen therapy R.S.SAWERS, VALERIE A.RANDALL* AND

More information

CARBON MONOXIDE POISONING

CARBON MONOXIDE POISONING CARBON MONOXIDE POISONING Matthew Valento, MD Assistant Professor, UW Department of Emergency Medicine Washington Poison Center Carbon monoxide (CO) Incomplete combustion of carbon-containing compounds

More information

Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men

Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Gonadal Steroids and Body Composition, Strength, and Sexual Function in Men Joel S. Finkelstein, M.D., Hang Lee, Ph.D., Sherri-Ann

More information

MATERIAL SAFETY DATA SHEET

MATERIAL SAFETY DATA SHEET Page 1 of 5 1. IDENTIFICATION OF THE SUBSTANCE/PREPARATION AND THE COMPANY/UNDERTAKING Pfizer Inc Pfizer Pharmaceuticals Group 235 East 42nd Street New York, New York 10017 1-212-573-2222 Emergency telephone

More information

Hospital Admissions in the Northern Territory

Hospital Admissions in the Northern Territory Hospital Admissions in the Northern Territory 1976-28 www.healthynt.nt.gov.au Hospital Admissions in the Northern Territory, 1976 to 28 Shu Qin Li Sabine Pircher Steve Guthridge John Condon Jo Wright Acknowledgements

More information

SOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS

SOP 407: PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS University of Oklahoma Office of Human Research Participant Protection : PROTOCOL DEVIATIONS AND UNANTICIPATED PROBLEMS 1. POLICY Protocol deviations and unanticipated problems may be discovered in a variety

More information

Corporate Medical Policy

Corporate Medical Policy File Name: hyperbaric_oxygen_therapy Origination: 4/1980 Last CAP Review: 11/2016 Next CAP Review: 11/2017 Last Review: 11/2016 Corporate Medical Policy Description of Procedure or Service Hyperbaric oxygen

More information

2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package

2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package 2019 Canada Winter Games Cross Country Ski & Para-Nordic Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility

More information

Oregon School Activities Association SW Parkway Avenue, Suite 1 Wilsonville, OR fax:

Oregon School Activities Association SW Parkway Avenue, Suite 1 Wilsonville, OR fax: Oregon School Activities Association 25200 SW Parkway Avenue, Suite 1 Wilsonville, OR 97070 503.682.6722 fax: 503.682.0960 http://www.osaa.org August 2, 2016 TO: FROM: SUBJECT: Superintendents, Principals

More information

Deca Durabolin. (Nandrolone Decanoate) Deca Durabolin Functions & Traits:

Deca Durabolin. (Nandrolone Decanoate) Deca Durabolin Functions & Traits: Deca Durabolin (Nandrolone Decanoate) Deca Durabolin is an extremely popular anabolic steroid comprised of the steroidal hormone Nandrolone and is attached to the large Decanoate ester. The Nandrolone

More information

Risks Versus Benefits of Testosterone Therapy in Elderly Men

Risks Versus Benefits of Testosterone Therapy in Elderly Men REVIEW ARTICLE Drugs & Aging 1999 Aug; 15 (2): 131-142 1170-229X/99/0008-0131/$06.00/0 Adis International Limited. All rights reserved. Risks Versus Benefits of Testosterone Therapy in Elderly Men Shehzad

More information

By Christopher Suprun Jr., NREMT-P, CCEMT-P

By Christopher Suprun Jr., NREMT-P, CCEMT-P By Christopher Suprun Jr., NREMT-P, CCEMT-P PHOTO FOR ILLUSTRATION ONLY. 34 Texas EMS Magazine March/April 2005 Pumped up Watching for signs of steroid use It s a quiet Saturday morning as your crew considers

More information

Castration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009

Castration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009 Castration resistant prostate cancer-what is it? and what do we do about it? Urology Postgraduate Course February 13, 2009 Charles J Ryan, MD Associate Professor of Clinical Medicine Helen Diller Family

More information

1 Identification of the substance / preparation and of the company / undertaking 1.1 Product Identification Trade name: Synonyms

1 Identification of the substance / preparation and of the company / undertaking 1.1 Product Identification Trade name: Synonyms Issued date: 01/December/ 2010 Document: SDS-DT-01-02 Page 1 of 5 1 Identification of the substance / preparation and of the company / undertaking 1.1 Product Identification Trade name: Synonyms Gonadotrophin,

More information

OHRP Guidance on Written IRB Procedures

OHRP Guidance on Written IRB Procedures Office for Human Research Protections (OHRP) Department of Health and Human Services Date: OHRP Guidance on Written IRB Procedures Scope: This document outlines the required elements of written Institutional

More information

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 11/2017

See 17 for PATIENT COUNSELING INFORMATION and FDAapproved. Revised: 11/2017 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JALYN safely and effectively. See full prescribing information for JALYN. JALYN (dutasteride and

More information

2017 Canada Summer Games Golf Technical Package

2017 Canada Summer Games Golf Technical Package 2017 Canada Summer Games Golf Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility requirements, assist

More information

X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism. Printed in U.S.A. Copyright 2000 by The Endocrine Society

X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism. Printed in U.S.A. Copyright 2000 by The Endocrine Society 0021-972X/00/$03.00/0 Vol. 85, No. 8 The Journal of Clinical Endocrinology & Metabolism rinted in U.S.A. Copyright 2000 by The Endocrine Society Effects of Testosterone Replacement in Hypogonadal Men*

More information

Hair Testing to provide additional evidence in doping cases of potential (clenbuterol) contaminations

Hair Testing to provide additional evidence in doping cases of potential (clenbuterol) contaminations Hair Testing to provide additional evidence in doping cases of potential (clenbuterol) contaminations Detlef Thieme Institute of Doping Analysis, Dresden, Germany Beijing, Oct 2017 [M. Jahn (www.kreischa.net)]

More information

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING. : ASTRAZENECA P.O. Box Wilmington, DE USA

1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING. : ASTRAZENECA P.O. Box Wilmington, DE USA SAFETY DATA SHEET 1. IDENTIFICATION OF THE SUBSTANCE/MIXTURE AND OF THE COMPANY/UNDERTAKING Product identifier ZOLADEX FOR DEPOT/IMPLANT Details of the supplier of the safety data sheet : ASTRAZENECA P.O.

More information

Evaluate the evidence for and against the use of testosterone to extend lifespan

Evaluate the evidence for and against the use of testosterone to extend lifespan 1 Evaluate the evidence for and against the use of testosterone to extend lifespan Background and introduction Testosterone is a steroid hormone which was first isolated in 1935 (David, Dingemanse, Freud

More information

2019 Canada Winter Games Synchronized Swimming Technical Package

2019 Canada Winter Games Synchronized Swimming Technical Package 2019 Canada Winter Games Synchronized Swimming Technical Package Technical Packages are a critical part of the Canada Games. They guide the selection of athletes by prescribing the age and eligibility

More information

Summary. Introduction. Dow Stough, MD

Summary. Introduction. Dow Stough, MD Original Contribution Blackwell Publishing ORIGINAL Inc CONTRIBUTION Dutasteride improves male pattern hair loss in a randomized study in identical twins Dow Stough, MD The Dermatology Clinic, Hot Springs,

More information

26-G Keewaydin Drive, Salem, NH P: (800) F: (603)

26-G Keewaydin Drive, Salem, NH P: (800) F: (603) Dihydrotestosterone ELISA For the quantitative determination of DHT in serum. For Research Use Only. Not for Use in Diagnostic Procedures. Catalog Number: 11-DHTHU-E01 Size: 96 wells Version: 4.1 August

More information

Acute hormonal response to sublingual androstenediol intake in young men

Acute hormonal response to sublingual androstenediol intake in young men J Appl Physiol 92: 142 146, 2002. Acute hormonal response to sublingual androstenediol intake in young men GREGORY A. BROWN, 1 EMILY R. MARTINI, 1 B. SCOTT ROBERTS, 1 MATTHEW D. VUKOVICH, 2 AND DOUGLAS

More information

Dutasteride Avodart Softgel Capsule

Dutasteride Avodart Softgel Capsule Dutasteride Avodart Softgel Capsule PRODUCT DESCRIPTION Dutasteride (Avodart ) is available as dull yellow, opaque, oblong soft gelatin capsules containing a clear, colourless to slightly yellow liquid.

More information

WHY THE USE OF EITHER 5ALPHA REDUCTASE (5AR) INHIBITORS DUTASTERIDE/AVODART (MY CHOICE) OR FINASTERIDE/PROSCAR IN ANDROGEN DEPRIVATION THERAPY?

WHY THE USE OF EITHER 5ALPHA REDUCTASE (5AR) INHIBITORS DUTASTERIDE/AVODART (MY CHOICE) OR FINASTERIDE/PROSCAR IN ANDROGEN DEPRIVATION THERAPY? WHY THE USE OF EITHER 5ALPHA REDUCTASE (5AR) INHIBITORS DUTASTERIDE/AVODART (MY CHOICE) OR FINASTERIDE/PROSCAR IN ANDROGEN DEPRIVATION THERAPY? by Charles (Chuck) Maack, Prostate Cancer Activist/Mentor

More information

Alberta Cancer Registry

Alberta Cancer Registry C A N C E R C A R E Alberta Cancer Registry 2007 Annual Report of Cancer Statistics ISSN: 1705-0251 June 2010 1 Alberta Cancer Registry 2007 Annual Report of Cancer Statistics Contents About The Alberta

More information

ANDROGENIC STEROIDS such as T and its derivatives

ANDROGENIC STEROIDS such as T and its derivatives 0013-7227/01/$03.00/0 The Journal of Clinical Endocrinology & Metabolism 86(11):5108 5117 Printed in U.S.A. Copyright 2001 by The Endocrine Society CLINICAL REVIEW 138 Anabolic-Androgenic Steroid Therapy

More information